Kusum Pandey

TL;DR: The risk of oversaturating endogenous small RNA pathways can be minimized by optimizing shRNA dose and sequence, as exemplified here by the report of persistent and therapeutic RNAi against human hepatitis B virus in vivo.

TL;DR: In this article, RNA interference was applied to inhibit production of HBV replicative intermediates in cell culture and in immunocompetent and immunodeficient mice transfected with an HBV plasmid.

TL;DR: Use of LamR, which is constitutively expressed in many clinically relevant tissues and is overexpressed in numerous cancers, provides a molecular explanation for AAV8's broad tissue tropism and support the continued development of A AV8-based vectors for clinical applications in humans, especially for tumor gene therapy.

TL;DR: It is concluded that, unlike serotypes, AAV genotypes are not critical for efficient hepatocyte transduction and can be freely substituted and corroborates the current model for AAV vector persistence in the liver and provides useful information for the future design and application of recombinant AAV.

TL;DR: The results indicate that recognition of the Ad capsid or double-stranded DNA in the vector elicits a robust type I IFN response that is, however, not elicited by AAV-derived vector transduction.